Skip to main content
SpringerLink
Log in

Evaluation and Management of Skin Disease

  • Chapter
  • First Online:
Scleroderma

Abstract

The term “scleroderma” originates from the Greek word sklerosis, meaning hardness, and derma, meaning skin. The skin hardening in diffuse, limited, and localized forms of scleroderma is the most clinically evident aspect of the disease and creates significant functional and emotional challenges for patients. The dermal fibrosis that causes hardening of the skin in these diseases is also associated with distressing disfigurement, dyspigmentation, and dysregulation of normal skin functions such as sweating and oil production. The sclerotic areas of skin can develop ulcerations, infection, or calcifications that can lead to significant morbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

References

  1. Weedon D. Skin pathology. 2nd ed. Philadelphia: Elsevier Health; 2005. p. 347–50.

    Google Scholar 

  2. Sherber NS, Boin F, Hummers LK, Wigley FM. The “tank top sign” – a unique pattern of skin fibrosis seen in pansclerotic morphea. Ann Rheum Dis. 2009;68(9):1511–2.

    Article  PubMed  CAS  Google Scholar 

  3. Barnett AJ. The “neck sign” in scleroderma. Arthritis Rheum. 1989;32(2):209–11.

    Article  PubMed  CAS  Google Scholar 

  4. Beyer C, Schett G, Gay S, Distler O, Distler JH. Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis. Arthritis Res Ther. 2009;11(2):220.

    Article  PubMed  Google Scholar 

  5. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.

    PubMed  CAS  Google Scholar 

  6. Amjadi S, Maranian P, Furst DE, Clements PJ, Wong WK, Postlethwaite AE, Khanna PP, Khanna D. Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. Arthritis Rheum. 2009;60:2490–8.

    Article  PubMed  Google Scholar 

  7. Kowal-Bielecka O, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009;68(5):620–8.

    Article  PubMed  CAS  Google Scholar 

  8. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol. 2009;10(3):181–7.

    Article  PubMed  Google Scholar 

  9. McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2010;27(5):425–36.

    Article  PubMed  Google Scholar 

  10. Keuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440–7.

    Article  Google Scholar 

  11. Dytoc M, Ting PT, Man J, Sawyer D, Fiorillo L. First case series on the use of imiquimod for morphoea. Br J Dermatol. 2005;153(4):815–20.

    Article  PubMed  CAS  Google Scholar 

  12. Usmani N, Murphy A, Veale D, Goulden V, Goodfield M. Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers. Clin Exp Dermatol. 2010;35(6):608–13.

    Article  PubMed  CAS  Google Scholar 

  13. Patel RV, Clark LN, Lebwohl M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. J Am Acad Dermatol. 2009;60(6):1001–7.

    Article  PubMed  Google Scholar 

  14. Grundmann-Kollmann M, Ochsendorf F, Zollner TM, Spieth K, Sachsenberg-Studer E, Kaufmann R, Podda M. PUVA-cream photochemotherapy for the treatment of localized scleroderma. J Am Acad Dermatol. 2000;43(4):675–8.

    Article  PubMed  CAS  Google Scholar 

  15. Morison W. Phototherapy and photochemotherapy of skin disease. 3rd ed. Boca Raton: Taylor & Francis; 2005. p. 225.

    Google Scholar 

  16. Durand F, Staumont D, Bonnevalle A, Hachulla E, Hatron PY, Thomas P. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed. 2007;23(6):215–21.

    Article  PubMed  CAS  Google Scholar 

  17. Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol. 2001;45(5):697–9.

    Article  PubMed  CAS  Google Scholar 

  18. Eisen D, Alster T. Use of a 585 nm pulsed dye laser for the treatment of morphea. Dermatol Surg. 2002;28(7):615–6.

    Article  PubMed  Google Scholar 

  19. Rencic A, Brinster N, Nousari CH. Keloid morphea and nodular scleroderma: two distinct clinical variants of scleroderma? J Cutan Med Surg. 2003;7(1):20–4.

    Article  PubMed  Google Scholar 

  20. Braverman IM, Ken-Yen A. Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. J Invest Dermatol. 1983;81(6):489–97.

    Article  PubMed  CAS  Google Scholar 

  21. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37(1):98–104.

    Article  PubMed  Google Scholar 

  22. Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Läuchli S. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol. 2007;21(4):504–8.

    PubMed  CAS  Google Scholar 

  23. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139(5):581–5.

    Article  PubMed  CAS  Google Scholar 

  24. Meissner M, Ochsendorf F, Kaufmann R. Letter: therapy of calcinosis cutis using erbium-doped yttrium aluminum garnet laser treatment. Dermatol Surg. 2010;36:727–8.

    Article  PubMed  CAS  Google Scholar 

  25. Chamberlain AJ, Walker NPJ. Successful palliation and significant remission of cutaneous calcinosis in CREST syndrome with carbon dioxide laser. Dermatol Surg. 2003;29:968–70.

    Article  PubMed  Google Scholar 

  26. Wolf EK, Smidt AC, Laumann AE. Topical sodium thiosulfate therapy for leg ulcers with dystrophic calcification. Arch Dermatol. 2008;144(12):1560–2.

    Article  PubMed  Google Scholar 

  27. Lee JC, Kandula S, Sherber NS. Beyond wet-to-dry: a rational approach to treating chronic wounds. Eplasty. 2009;9:e14.

    PubMed  Google Scholar 

  28. Sherber NS, Wigley FM, Scher RK. Autoimmune disorders: nail signs and therapeutic approaches. Dermatol Ther. 2007;20:17–30.

    Article  PubMed  Google Scholar 

  29. Onesti MG, Troccola A, Scuderi N. Volumetric correction using poly-L-lactic acid in facial asymmetry: Parry Romberg syndrome and scleroderma. Dermatol Surg. 2009;35(9):1368–75.

    Article  PubMed  CAS  Google Scholar 

  30. Hairston BR, Davis MDP, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142:1413–8.

    Article  PubMed  Google Scholar 

  31. Weinstein S, Piette W. Cutaneous manifestations of antiphospholipid antibody syndrome. Hematol Oncol Clin North Am. 2008;22(1):67–77. vi. Review.

    Article  PubMed  Google Scholar 

  32. Tierney EP, Hancke CW. Review of the literature: treatment of dyspigmentation with fractionated resurfacing. Dermatol Surg. 2010;36(10):1499–508.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scleroderma Center, Johns Hopkins Hospital, Baltimore, MD, USA

    Noëlle Starr Sherber MD, FAAD

Authors
  1. Noëlle Starr Sherber MD, FAAD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noëlle Starr Sherber MD, FAAD .

Editor information

Editors and Affiliations

  1. Feinberg School of Medicine, Northwestern University, E. Huron Street 240, Chicago, 60611-2909, Illinois, USA

    John Varga

  2. Royal Free and University College, Medical School, University College London, Rowland Street, London, NW3 2PF, United Kingdom

    Christopher P. Denton

  3. School of Medicine, Div. Rheumatology, Johns Hopkins University, Eastern Avenue 5200, Baltimore, 21224, Maryland, USA

    Fredrick M. Wigley

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sherber, N.S. (2012). Evaluation and Management of Skin Disease. In: Varga, J., Denton, C., Wigley, F. (eds) Scleroderma. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-5774-0_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-5774-0_42

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-5773-3

  • Online ISBN: 978-1-4419-5774-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation